Target Price | €641.00 |
Price | €358.00 |
Potential |
79.05%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a Limes Schlosskliniken price target 2026.
The average Limes Schlosskliniken target price is €641.00.
This is
79.05%
register free of charge
|
|
A rating was issued by 5 analysts: 4 Analysts recommend Limes Schlosskliniken to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Limes Schlosskliniken stock has an average upside potential 2026 of
79.05%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million € | 38.12 | 56.77 |
0.42% | 48.92% | |
EBITDA Margin | 18.49% | 24.84% |
8.47% | 34.31% | |
Net Margin | 8.16% | 14.05% |
8.91% | 72.21% |
2 Analysts have issued a sales forecast Limes Schlosskliniken 2025 . The average Limes Schlosskliniken sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Limes Schlosskliniken EBITDA forecast 2025. The average Limes Schlosskliniken EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Limes Schlosskliniken Analysts have issued a net profit forecast 2025. The average Limes Schlosskliniken net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share € | 10.61 | 27.49 |
8.38% | 159.10% | |
P/E | 12.95 | |
EV/Sales | 1.93 |
2 Analysts have issued a Limes Schlosskliniken forecast for earnings per share. The average Limes Schlosskliniken EPS is
This results in the following potential growth metrics and future valuations:
Limes Schlosskliniken...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.